Arpita Dutt | TalkMarkets | Page 3

Arpita Dutt

Analyst at Zacks Research Pvt. Ltd.
Contributor's Links: Zacks Investment Research
Arpita has been an equity analyst at Zacks Investment Research since March, 2004.
Following: 12 Followers: 1915

All Contributions

Latest Posts
33 to 48 of 92 Posts
<<< 1 2 3 4 5 6 >>>
3 Hot Biotech Stocks To Buy In June
Thursday, June 1, 2017 11:29 AM EDT
While drug pricing will remain a headline risk until some plan is announced by the administration, here are a few biotech stocks that have performed well YTD and look well-positioned.
In this article: REGN, SGMO, PBYI
Read
5 Drug Stocks In Focus On World MS Day
Wednesday, May 31, 2017 11:23 AM EDT
The multiple sclerosis market represents huge commercial potential. Here are some of the key players in the MS market.
In this article: BIIB, TEVA, NVS, SNY, RHHBY
Read
Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses In Pivotal Study
Friday, May 12, 2017 10:52 AM EDT
This week, companies like Mylan, Allergan and Teva reported earnings results. The spotlight also remained on Roche which saw its immuno-oncology drug fail in a pivotal study.
In this article: AZN, MRK, PFE, RHHBY, MYL, TEVA
Read
Celgene Vs. Amgen: Which Stock Is A Better Pick Post Q1 Earnings?
Wednesday, May 3, 2017 2:44 PM EDT
Last week, two major names in the biotech sector reported first quarter 2017 results -- Amgen, Inc. and Celgene Corporation. Here is a look at how both companies fared in the first quarter and which one looks better-positioned.
In this article: AMGN, CELG
Read
Pharma Stock Roundup: Merck Gets CRL For Label Expansion Effort, Roche Cancer Drug Tops
Friday, April 14, 2017 12:00 PM EDT
It was a relatively slow week with key highlights including a complete response letter (CRL) for Merck’s label expansion efforts for its diabetes drugs and positive data on Roche’s lung cancer treatment.
In this article: AZN, JNJ, MRK, MYL, RHHBY, PFE, BMY
Read
Biotech Stock Roundup: Geron Gains On Interim Data, OncoMed Slumps On Pipeline Setback
Wednesday, April 12, 2017 10:13 AM EDT
Several companies including Geron and OncoMed provided key pipeline updates this week. While Geron’s shares were up this week, OncoMed’s shares plunged and hit a 52-week low.
In this article: GERN, INCY, REGN, CELG, GILD, VRTX, OMED
Read
3 Of The Best & Worst Performing Drug Stocks Of Q1
Thursday, April 6, 2017 11:37 AM EDT
Pharma and biotech stocks have been showing signs of recovery this year. The sector started the year on a strong note with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 10.7% and 5.7%, in the first quarter of 2017.
In this article: ESPR, VRTX, NKTR, CDTX, XENE
Read
3 Housing Stocks To Buy On Sharp Rebound In Pending Home Sales
Thursday, March 30, 2017 11:28 AM EDT
The February data is a marked improvement from January when insufficient supply levels, as well as deteriorating affordability, had led to a 2.8% dip in the Pending Home Sales Index.
In this article: KBH, LEN, PHM
Read
3 Biotech Stocks That Are Broker Favorites
Tuesday, March 21, 2017 12:23 PM EDT
Biotech stocks, which have been showing signs of recovery this year, slipped last week following the release of the Budget Blueprint for 2018.
In this article: BPMC, CLLS, MATN Also: BIIB, AMGN
Read
After Valeant, Here Are 5 Drug Stocks Bill Ackman Should Buy Instead
Wednesday, March 15, 2017 12:57 PM EDT
Here is a look at 5 drug stocks that could find a place in Ackman’s investment plans.
In this article: NEOS, CNCE, LOXO, NDRM, BCRX Also: VRX
Read
How Incyte Stock Became A Bull Market Star For Biotech Investors
Friday, March 10, 2017 9:17 AM EDT
Despite many twists and turns, the U.S. stock market has had a stupendous run since it reached a bottom in Mar 2009. The bull run has continued for eight years with the S&P 500 gaining 198.1% during this period.
In this article: INCY Also: GILD, NVS, LLY, MRK, RHHBY, AZN
Read
Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains On Vertex Deal
Wednesday, March 8, 2017 9:08 AM EDT
A tweet kept the biotech industry on edge with President Donald Trump declaring that he is “working on a new system where there will be competition in the Drug Industry” and “pricing for the American people will come way down”.
In this article: CNCE, IONS, JUNO, CELG Also: VRTX, GILD, BIIB
Read
Is This The Right Time To Invest In Biotech Stocks?
Tuesday, March 7, 2017 11:06 AM EDT
A look at the industry’s year-to-date (YTD) price performance indicates that the sector is showing signs of recovery. But, will the rally continue and is this the right time to put your money in this corner of the market?
In this article: ALXN, BIIB, GILD, CELG
Read
5 FDA Decisions To Watch Out For In Mar 2017
Monday, March 6, 2017 12:09 PM EDT
The FDA, which gave its nod to 22 treatments last year, has given it's approval to 5 drugs so far in 2017. Here is a look at a few important regulatory events scheduled for the month of March.
In this article: MRK, RHHBY, REGN, SNY, RDUS Also: AMGN, VRX
Read
5 Drug Stocks Poised To Beat Earnings Estimates In Q4
Thursday, February 9, 2017 11:11 AM EDT
A positive earnings picture continues to emerge from the fourth-quarter earnings season with both earnings and revenue growth improving compared to recent quarters.
In this article: EXEL, INCY, JAZZ, IRWD, AKAO
Read
Biotech Stock Roundup: Celgene, Biogen, ABBV Posted Q4 Results, Catabasis Falls On DMD Data
Thursday, February 2, 2017 8:56 AM EDT
Companies like Celgene, Biogen and AbbVie reported fourth quarter results last week. Catabasis suffered a major setback with its lead pipeline candidate edasalonexent failing to meet the primary endpoint.
In this article: REGN, XOMA, AMGN, BIIB, CELG, CATB, ABBV
Read
33 to 48 of 92 Posts
<<< 1 2 3 4 5 6 >>>